Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Expression of Fibroblast Growth Factor 23, Vitamin D Receptor, and Sclerostin in Bone Tissue from Hypercalciuric Stone Formers

Full text
Author(s):
Menon, Viviane Barcellos [1] ; Affonso Moyses, Rosa Maria [2] ; Gomes, Samirah Abreu [1] ; de Carvalho, Aluizio Barbosa [1] ; Jorgetti, Vanda [2] ; Heilberg, Ita Pfeferman [1]
Total Authors: 6
Affiliation:
[1] Univ Fed Sao Paulo, Div Nephrol, BR-04023900 Sao Paulo - Brazil
[2] Univ Sao Paulo, Div Nephrol, Sao Paulo - Brazil
Total Affiliations: 2
Document type: Journal article
Source: Clinical Journal of the American Society of Nephrology; v. 9, n. 7, p. 1263-1270, JUL 7 2014.
Web of Science Citations: 6
Abstract

Background and objectives Increased bone resorption, low bone formation, and abnormal mineralization have been described in stone formers with idiopathic hypercalciuria. It has been previously shown that the receptor activator of NF-kappa B ligand mediates bone resorption in idiopathic hypercalciuria (IH). The present study aimed to determine the expression of fibroblast growth factor 23 (FGF-23), vitamin D receptor (VDR), and sclerostin in bone tissue from IH stone formers. Design, setting, participants, \& measurements Immunohistochemical analysis was performed in undecalcified bone samples previously obtained for histomorphometry from 30 transiliac bone biopsies of idiopathic hypercalciuria stone-forming patients between 1992 and 2002 and 33 healthy individuals (controls). Serum parameters were obtained from their medical records. Results Histomorphometry disclosed 21 IH patients with high and 9 IH patients with normal bone resorption. Importantly, eroded surfaces (ES/BS) from IH patients but not controls were significantly correlated with VDR immunostaining in osteoblasts (r=0.51; P=0.004), sclerostin immunostaining in osteocytes (r=0.41; P=0.02), and serum 1,25-dihydroxyvitamin D (r=0.55; P<0.01). Of note, both VDR and sclerostin immunostaining were significantly correlated with serum 1,25-dihydroxyvitamin D in IH patients (r=0.52; P=0.01 and r=0.53; P=0.02, respectively), although VDR and sclerostin expression did not differ between IH and controls. IH patients with high bone resorption exhibited a significantly stronger sclerostin immunostaining than IH patients with normal bone resorption. FGF-23 expression in osteocytes from IH patients did not differ from controls and was not correlated with any histomorphometric parameter. Conclusions These findings suggest the contribution of VDR and sclerostin, as well as 1,25-dihydroxyvitamin D, to increase bone resorption in idiopathic hypercalciuria but do not implicate FGF-23 in the bone alterations seen in these patients. (AU)

FAPESP's process: 08/10515-0 - Expression of vitamin D receptor (VDR), parathyroid hormone (PTH)/PTH-related peptide receptor type 1(PTHR1), calcium sensing receptor (CaSR) and fibroblast growth factor 23 (FGF-23) in bone tissue in hypercalciuric stone forming patients
Grantee:Ita Pfeferman Heilberg
Support Opportunities: Regular Research Grants